Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Bioventus (NASDAQ:BVS) and raises the price target from $8 to $12.
August 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Bioventus and raises the price target from $8 to $12.
The raised price target from $8 to $12 by a reputable analyst is a positive signal for investors, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100